Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 11, 2025Therapeutic Advances in Medical OncologyOpen Access

Comparing two different doses of inotuzumab ozogamicin treatment in adult patients with acute lymphoblastic leukemia: a plain language summary of publication

View Full Paper
Ask AI
Bookmark
Share

Authors

MÖMuhıt ÖzcanRCRyan D. CassadayEZEwa Zarzycka

Discussion

Loading...

Member takes

Overview

Clinical study compares efficacy and side effects of inotuzumab doses in adults with ALL, suggesting dosages impact outcomes.

Key Points

  • Lower doses of inotuzumab may reduce the incidence of sinusoidal obstruction syndrome after treatment.
  • Participants in the study were adults aged 18 and older with acute lymphoblastic leukemia, evaluating potential side effects.
  • The research aimed to assess both efficacy and side effects of different doses of inotuzumab in treating ALL.
  • Exploring the relationship between dosage and veno-occlusive disease can inform future treatment protocols for ALL.

Cite This Study

Özcan et al. (2025) studied this question.

synapsesocial.com/papers/68e9b1c1ba7d64b6fc132491https://doi.org/10.1177/17588359251370948
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-World Data on Inotuzumab Ozogamicin for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A GRELAL-Chile Study.2025 · 2 citations
  2. 2Efficacy and Toxicity of Inotuzumab Ozogamicin for Treatment of Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia in Pediatric and Young Adult Patients After CD19‐Chimeric Antigen Receptor T‐Cell Therapy2025 · 1 citations
  3. 3A real-world multi-institution experience of standard vs alternative dosing of inotuzumab ozogamicin for Relapsed/Refractory pediatric B-cell acute lymphoblastic leukemia2025
  4. 4A retrospective analysis of inotuzumab ozogamicin usage in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia2025 · 1 citations
  5. 5Efficacy and safety of inotuzumab ozogamicin combined with venetoclax and dexamethasone in relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)2025 · 1 citations